TY - JOUR
T1 - Subcutaneous undifferentiated pleomorphic sarcoma is more aggressive than pleomorphic dermal sarcoma
T2 - Prognosis from a Danish nationwide registry-based cohort
AU - Ørholt, Mathias
AU - Wulff, Ida
AU - Abebe, Kiya
AU - Weltz, Tim K
AU - Hemmingsen, Mathilde N
AU - Wagenblast, Anne L
AU - Schmidt, Grethe
AU - Jensen, David H
AU - Petersen, Michael M
AU - Loya, Anand C
AU - Daugaard, Søren
AU - Mentzel, Thomas
AU - Herly, Mikkel
AU - Vester-Glowinski, Peter
N1 - Copyright © 2025. Published by Elsevier Ltd.
PY - 2025/7
Y1 - 2025/7
N2 - INTRODUCTION: Subcutaneous undifferentiated pleomorphic sarcoma (scUPS) has not previously been described separately from pleomorphic dermal sarcoma (PDS), and consequently the prognosis for patients with scUPS is unknown.MATERIALS AND METHODS: In this nationwide cohort study, we identified all patients in Denmark diagnosed with scUPS or PDS between 2002 and 2022. The outcomes were 5-year local recurrence, loco-regional and distant metastasis, and overall survival.RESULTS: We included 271 patients, 131 with scUPS and 140 with PDS. Patients with scUPS exhibited higher 5-year risks than patients with PDS in terms of the overall risk of metastasis (19 % vs. 7 %, p = 0.006) and distant metastasis only (12 % vs. 2 %, p = 0.004). The 5-year overall survival for patients with scUPS was 50 %, compared to 67 % for patients with PDS (p = 0.004).CONCLUSION: Our findings indicate that patients with scUPS have a significantly worse prognosis than patients with PDS, with a higher overall risk of metastasis and a prolonged metastatic risk. This suggests a more extended follow-up program focusing on the detection of distant metastasis for patients with scUPS, whereas the follow-up of patients with PDS can be limited to clinical controls.
AB - INTRODUCTION: Subcutaneous undifferentiated pleomorphic sarcoma (scUPS) has not previously been described separately from pleomorphic dermal sarcoma (PDS), and consequently the prognosis for patients with scUPS is unknown.MATERIALS AND METHODS: In this nationwide cohort study, we identified all patients in Denmark diagnosed with scUPS or PDS between 2002 and 2022. The outcomes were 5-year local recurrence, loco-regional and distant metastasis, and overall survival.RESULTS: We included 271 patients, 131 with scUPS and 140 with PDS. Patients with scUPS exhibited higher 5-year risks than patients with PDS in terms of the overall risk of metastasis (19 % vs. 7 %, p = 0.006) and distant metastasis only (12 % vs. 2 %, p = 0.004). The 5-year overall survival for patients with scUPS was 50 %, compared to 67 % for patients with PDS (p = 0.004).CONCLUSION: Our findings indicate that patients with scUPS have a significantly worse prognosis than patients with PDS, with a higher overall risk of metastasis and a prolonged metastatic risk. This suggests a more extended follow-up program focusing on the detection of distant metastasis for patients with scUPS, whereas the follow-up of patients with PDS can be limited to clinical controls.
KW - Follow-up
KW - Local recurrence
KW - Metastasis
KW - Outcomes
KW - Overall survival
KW - Pleomorphic dermal sarcoma
KW - Prognosis
KW - Skin cancer
KW - Subcutaneous undifferentiated pleomorphic sarcoma
UR - http://www.scopus.com/inward/record.url?scp=86000283590&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2025.109747
DO - 10.1016/j.ejso.2025.109747
M3 - Journal article
C2 - 40057991
SN - 0748-7983
VL - 51
SP - 109747
JO - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
JF - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
IS - 7
M1 - 109747
ER -